Itching for good outcomes.
We’re all familiar with the favorable predictive nature of experiencing a skin reaction while on cetuximab. Can the same be said with immune checkpoint inhibition? This retrospective look at an international population-based database included over 7000 patients with a documented cutaneous adverse event while on ICI for various cancer diagnoses and compared outcomes. When compared to matched controls without cutaneous side effects, those with side effects had significantly longer survival times. What’s more, with the exception of mucositis and hyperhidrosis, this held true across nearly a dozen individual dermatoses investigated. | Tang, JAMA Dermatol 2022